Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report

Kristofoor E Leeuwenberg; Rob Ter Heine; Johanna M M Gijtenbeek; Michel M van den Heuvel

doi:10.1159/000541988

Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report

Kristofoor E Leeuwenberg
, Rob Ter Heine
, Johanna M M Gijtenbeek
, Michel M van den Heuvel

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

INTRODUCTION: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.

CASE PRESENTATION: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.

CONCLUSION: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.

Original language	English
Pages (from-to)	1289-1293
Number of pages	5
Journal	Case Reports in Oncology
Volume	17
Issue number	1
DOIs	https://doi.org/10.1159/000541988
Publication status	Published - 2024
Externally published	Yes

Access to Document

10.1159/000541988

Cite this

@article{d671141b5238431fa8b28c98c214b60b,

title = "Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report",

abstract = "INTRODUCTION: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.CASE PRESENTATION: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.CONCLUSION: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.",

author = "Leeuwenberg, \{Kristofoor E\} and \{Ter Heine\}, Rob and Gijtenbeek, \{Johanna M M\} and \{van den Heuvel\}, \{Michel M\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by S. Karger AG, Basel.",

year = "2024",

doi = "10.1159/000541988",

language = "English",

volume = "17",

pages = "1289--1293",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Polyradiculitis as a Neurological Complication Associated with Adagrasib

T2 - A Case Report

AU - Leeuwenberg, Kristofoor E

AU - Ter Heine, Rob

AU - Gijtenbeek, Johanna M M

AU - van den Heuvel, Michel M

PY - 2024

Y1 - 2024

N2 - INTRODUCTION: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.CASE PRESENTATION: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.CONCLUSION: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.

AB - INTRODUCTION: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.CASE PRESENTATION: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.CONCLUSION: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.

U2 - 10.1159/000541988

DO - 10.1159/000541988

M3 - Article

C2 - 39534868

SN - 1662-6575

VL - 17

SP - 1289

EP - 1293

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report

Abstract

Access to Document

Fingerprint

Cite this